Mwanzo87S • FRA
add
Roivant Sciences Ltd
Bei iliyotangulia
€ 8.69
Bei za siku
€ 8.65 - € 8.70
Bei za mwaka
€ 7.98 - € 12.11
Thamani ya kampuni katika soko
7.44B USD
Wastani wa hisa zilizouzwa
4.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 9.02M | -42.05% |
Matumizi ya uendeshaji wa biashara | 132.34M | 31.07% |
Mapato halisi | 169.38M | -96.68% |
Kiwango cha faida halisi | elfu 1.88 | -94.26% |
Mapato kwa kila hisa | -0.20 | 4.01% |
EBITDA | -261.54M | -42.81% |
Asilimia ya kodi ya mapato | 10.90% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 5.15B | -22.85% |
Jumla ya mali | 5.79B | -20.79% |
Jumla ya dhima | 256.38M | -64.79% |
Jumla ya hisa | 5.54B | — |
hisa zilizosalia | 713.55M | — |
Uwiano wa bei na thamani | 1.20 | — |
Faida inayotokana na mali | -10.98% | — |
Faida inayotokana mtaji | -11.69% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 169.38M | -96.68% |
Pesa kutokana na shughuli | -207.25M | 1.52% |
Pesa kutokana na uwekezaji | 454.07M | -91.32% |
Pesa kutokana na ufadhili | -272.95M | -215.34% |
Mabadiliko halisi ya pesa taslimu | -27.20M | -100.52% |
Mtiririko huru wa pesa | -303.56M | -321.65% |
Kuhusu
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
7 Apr 2014
Tovuti
Wafanyakazi
908
